These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12030311)

  • 41. Neuropsychological performance in Alzheimer's disease and vascular dementia: comparisons in a memory clinic population.
    Baillon S; Muhommad S; Marudkar M; Suribhatla S; Dennis M; Spreadbury C; Munro D; Lindesay J
    Int J Geriatr Psychiatry; 2003 Jul; 18(7):602-8. PubMed ID: 12833304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
    Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
    Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):65-7. PubMed ID: 19938276
    [No Abstract]   [Full Text] [Related]  

  • 44. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relevance of the serial position effect in the differential diagnosis of mild cognitive impairment, Alzheimer-type dementia, and normal ageing.
    Martín ME; Sasson Y; Crivelli L; Roldán Gerschovich E; Campos JA; Calcagno ML; Leiguarda R; Sabe L; Allegri RF
    Neurologia; 2013 May; 28(4):219-25. PubMed ID: 22695314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Donepezil in vascular dementia: a randomized, placebo-controlled study.
    Wilkinson D; Doody R; Helme R; Taubman K; Mintzer J; Kertesz A; Pratt RD;
    Neurology; 2003 Aug; 61(4):479-86. PubMed ID: 12939421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Memory factors in Rey AVLT: Implications for early staging of cognitive decline.
    Fernaeus SE; Ostberg P; Wahlund LO; Hellström A
    Scand J Psychol; 2014 Dec; 55(6):546-53. PubMed ID: 25112600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia.
    Di Perri R; Coppola G; Ambrosio LA; Grasso A; Puca FM; Rizzo M
    J Int Med Res; 1991; 19(4):330-41. PubMed ID: 1916007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient populations in clinical studies of donepezil in vascular dementia.
    Pratt RD
    Int Psychogeriatr; 2003; 15 Suppl 1():195-200. PubMed ID: 16191240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dementia severity and pattern of cognitive performance in vascular dementia.
    Paul R; Moser D; Cohen R; Browndyke J; Zawacki T; Gordon N
    Appl Neuropsychol; 2001; 8(4):211-7. PubMed ID: 11989724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic issues in vascular dementia: studies, designs and approaches.
    Black SE
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S125-30. PubMed ID: 17474183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia.
    Traykov L; Baudic S; Raoux N; Latour F; Rieu D; Smagghe A; Rigaud AS
    J Neurol Sci; 2005 Mar; 229-230():75-9. PubMed ID: 15760623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serial position effects in patients with mild cognitive impairment and early and moderate Alzheimer's disease compared with healthy comparison subjects.
    Moser B; Deisenhammer EA; Marksteiner J; Papousek I; Fink A; Weiss EM
    Dement Geriatr Cogn Disord; 2014; 37(1-2):19-26. PubMed ID: 24107650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.
    Brown ES; Gorman AR; Hynan LS
    J Clin Psychopharmacol; 2007 Oct; 27(5):498-502. PubMed ID: 17873684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivastigmine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD004744. PubMed ID: 15846730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.
    Xu QQ; Shan CS; Wang Y; Shi YH; Zhang QH; Zheng GQ
    J Alzheimers Dis; 2018; 62(1):429-456. PubMed ID: 29439346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serial position learning effects in patients with aneurysms of the anterior communicating artery.
    Stefanova E; Kostic VS; Ziropadja L; Markovic M; Ocic G
    J Clin Exp Neuropsychol; 2002 Aug; 24(5):687-94. PubMed ID: 12187451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.